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Abstract
HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best
characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4+ T cells carrying latent but replication-
competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-
validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different
approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4+
T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells
containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who
started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell
frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong
correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical
significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4+ T
cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays.
The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based
assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool
of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation
strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy
between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research.
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Introduction
Treatment of HIV-1 infection with highly active antiretroviral
therapy (HAART) can reduce plasma HIV-1 RNA levels in
treated patients to below the detection limit of clinical assays (50
copies of HIV-1 RNA/ml) [1–3]. The effective suppression of
viremia initially encouraged hopes that the virus could be
eradicated with two to three years of HAART [3]. However, a
latent form of HIV-1 infection persists in vivo [4,5]. A small fraction
of resting memory CD4+ T cells carry integrated viral genomes.
These cells do not produce virus particles while in the resting state,
but can give rise to replication-competent virus following cellular
activation [4,5]. These latently infected cells are rare but stable,
even in patients on prolonged HAART [6–11]. Interruption of
HAART leads to a rebound in viremia [12,13], typically from an
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archival variant [14]. The latent reservoir is widely recognized as
the major barrier to HIV-1 eradication [15].
Strategies aimed at reactivating latent virus and thereby acceler-
ating the clearance of the latent reservoir are now in advanced pre-
clinical testing or early clinical trials [15]. Approaches for the
reactivation of latent HIV-1 include T cell activating cytokines [16–
19], T cell receptor and T cell receptor signaling pathway agonists
[20–24], histone deacetylase inhibitors [25–27], DNA methylase
inhibitors [28,29], and compounds like 5-hydroxynaphthalene-1,4-
dione [30] and disulfiram [31]. A single dose of the histone
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) has
recently been shown to increase cell-associated HIV-1 RNA in CD4+
T cells from patients on HAART [32].
A major question for current and future trials of eradication
strategies is how to evaluate the effectiveness of the interventions.
The principal approach for quantifying HIV-1 persistence during
HAART is a viral outgrowth assay performed on highly purified
resting CD4+ T cells. These cells do not produce virus without
stimulation [4]. In the assay, limiting dilutions of resting CD4+ T
cells are stimulated with the mitogen phytohemagglutinin (PHA) or
with anti-CD3 plus anti-CD28 antibodies in the presence of
irradiated allogeneic peripheral blood mononuclear cells (PBMC)
[5,6,9,10,33]. These stimuli induce global T cell activation, which
reverses latency at least in a fraction of cells carrying integrated
HIV-1 genomes. The viruses released from these cells are expanded
in CD4+ lymphoblasts from HIV-1-negative donors and detected
after 2–3 weeks by an ELISA assay for HIV-1 p24 antigen in the
supernatant. This assay detects individual latently infected cells that
release replication-competent virus following cellular activation.
The frequency of latently infected cells, expressed in terms of
infectious units per million (IUPM) resting CD4+ T cells, is
determined using Poisson statistics and is on the order of 0.1–10
IUPM in most patients on long term HAART. The value of this
assay is that it detects cells that can, when activated, release viruses
capable of robust replication. It therefore provides a minimum
estimate of the frequency of latently infected cells that that must be
eliminated to ensure eradication and is used here as a standard for
comparison. In principle, this assay can also detect resting CD4+ T
cells harboring labile unintegrated forms of HIV-1 DNA [34,35],
although the frequency of cells containing unintegrated DNA
during HAART is low [36–38]. Although the viral outgrowth assay
has important advantages, it is expensive and labor intensive, and it
requires large amounts of blood (120–180 ml).
Alternative approaches generally involve PCR assays for HIV-1
DNA. Some of these assays distinguish between integrated
proviruses and unintegrated HIV-1 DNA [39,40]. A problem
with all PCR-based assays is that they fail to distinguish between
replication-competent and defective forms of the viral genome. A
significant but poorly characterized proportion of infected resting
CD4+ T cells contain proviruses that are defective, hypermutated,
or silenced [41,42]. PCR assays are now also being used to
quantify HIV-1 DNA in CD4+ T cells from the gut associated
lymphoid tissue (GALT), where the frequency of HIV-1 infection
is generally higher than in the blood [43,44]. Highly sensitive PCR
methods are also now used to quantify HIV-1 RNA in cells [32].
Free virus particles are also found in the plasma of patients on
HAART [45–47]. This residual viremia is an important indication
of ongoing virus production. Several studies have shown that
residual viremia is not reduced by treatment intensification [48–
50], and thus it is likely to reflect virus production from stable
reservoirs. For example, residual viremia could in part reflect virus
production by latently infected cells that have become activated.
It is currently unclear which assay(s) should be used to monitor
HIV-1 reservoirs in clinical trials of eradication strategies. The
development of a high-throughput scalable assay to measure the
latent reservoir in patients has been identified as a key priority in
HIV-1 eradication research [51]. Here we present a comparative
analysis of eleven different approaches for measuring for HIV-1
reservoirs in two well characterized cohorts of patients on long
term HAART. The goal of the study was to determine how these
assays correlate with the viral outgrowth assay. The results provide
insights into how reservoirs should be evaluated in future clinical
trials aimed at curing HIV-1 infection.
Results
Patient characteristics
The baseline characteristics of the cohort are shown in Table 1.
Of 30 study participants, 10 started HAART during acute or early
HIV-1 infection while the remaining 20 started HAART during
chronic infection. The mean (6SD) age was 53.269.6 years.
Patients starting therapy during acute/early infection were slightly
younger (47.869.3 vs. 55.968.7 years). The majority (76.7%) of
study subjects were white/non-Hispanic. The current CD4+ T cell
counts were not significantly different between patients starting
HAART during acute/early vs. chronic infection (7276287 vs.
6726144, P = 0.58). For patients starting HAART during chronic
infection, the CD4 nadir was 2026138 cells/ml. The average
duration of viral load suppression on HAART was 5.862.5 years
for patients starting HAART during acute/early infection and
8.064.2 years for patients starting HAART during chronic
infection. No patient in either cohort had a documented ‘‘blip’’
above 40 copies RNA/mL in the year preceding the blood draw.
Assay characteristics
Samples were processed, split, and sent to laboratories with
expertise in the assays described above. Each assay was developed
independently by the relevant laboratory, with different input
material, assay methodology, normalization method, statistical
characteristics, and caveats. These are indicated in Table 2. The
cell types analyzed and viral species detected in each assay are
indicated in Table 3. Except for the single copy assay for plasma
Author Summary
Efforts to cure HIV-1 infection have focused on a small pool
of CD4+ T cells that carry viral genetic information in a
latent form. These cells persist even in patients on optimal
antiretroviral therapy. Novel therapeutic strategies target-
ing latently infected cells are being developed, and
therefore practical assays for measuring latently infected
cells are urgently needed. These cells were discovered
using a virus culture assay in which the cells are induced to
release virus particles that are then expanded in culture.
This assay is difficult, time-consuming, and expensive. Here
we evaluate alternative approaches for measuring persis-
tent HIV-1, all of which rely on the detection of viral
genetic information using the polymerase chain reaction
(PCR). None of the PCR-based assays correlated precisely
with the virus culture assay. The fundamental problem is
that infected cell frequencies determined by PCR are at
least 2 logs higher than frequencies determined by the
culture assay. Much of this difference may be due to cells
carrying defective forms of the virus. These cells may not
be eliminated by strategies designed to target latently
infected cells. In this situation, successful clearance of
latently infected cells might be masked by a large
unchanging pool of cells carrying defective HIV-1.
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HIV-1 RNA, assay results are presented in the form of infected cell
frequencies to facilitate cross-assay comparisons. However, the cell
populations included and viral species detected in each assay
(Table 3) must be kept in mind in interpreting these frequencies.
The statistical characteristics of each assay, such as the coefficient
of variation, the limit of detection, and the dynamic range
(summarized in Table 2) are important considerations in choosing
assays to monitor viral persistence. For example, the coefficient of
variation for the viral outgrowth assay is considerably higher than
that for most PCR-based assays. Statistical characteristics must
also be considered in evaluating the correlations between the
results of different assays because problems related assay precision,
accuracy, and sensitivity can obscure correlations. Table 2 also
describes the primers used for each PCR assay. Negative results for
any single PCR assay on a given patient sample can reflect
sequence variation in the primer binding site [47].
Viral outgrowth assay
Replication-competent HIV-1 was isolated from purified resting
CD4+ T cells from peripheral blood in 29/30 study participants
(Figure 1). Infected cell frequencies showed a log normal
distribution with a geometric mean frequency of 0.64 IUPM,
consistent with previous reports [6,9,10,52]. Latently infected cells
were readily detected by this method in patients starting HAART
during acute/early HIV-1 infection (mean=0.28 IUPM). The
mean frequency of latently infected cells was significantly lower in
patients starting HAART in acute/early HIV-1 infection com-
pared to those starting during chronic infection (0.28 vs. 0.97
IUPM, P= 0.048), although there was substantial overlap between
the two populations (Figure 1). The frequency of latently infected
cells was not correlated with the time between infection and the
initiation of a suppressive HAART regimen (r = 0.18, P= 0.34),
suggesting that the size of the reservoir does not increase
continuously during untreated HIV-1 infection. For a single study
participant, replication-competent virus was not detected even
after repeat culture. Based on input cell number, the frequency of
latently infected cells in this patient was ,0.06 IUPM.
The limit of detection of this assay is determined by the input
number of resting CD4+ T cells. With a 180 ml blood sample, the
average yield of resting CD4+ T cells in millions was 28.3614.7.
With therapeutic strategies that reduce the reservoir by more than
1.5 logs, latently infected cells would no longer be detectable in the
majority of patients unless larger blood volumes or leukopheresis
samples were used (Figure 1).
HIV-1 DNA in PBMC
A simple approach for quantifying persistent HIV-1 is to
measure HIV-1 DNA using PCR in unfractionated PBMC. This
was done using a droplet digital PCR approach that has greater
accuracy than standard real time PCR methods, particularly with
low template numbers [53]. HIV-1 DNA was detected in 28/30
PBMC samples (Figure 1). Values varied over a ,2 log range with
a geometric mean value of 74 copies/106 PBMC for the entire
cohort. Two subjects (2113 and 2453) had values that were below
the limit of detection (2 copies/106 PBMC). Interestingly, for these
two subjects, cells with replication-competent virus were readily
measured in the virus outgrowth assay (5.4 and 0.1 IUPM,
respectively). HIV-1 DNA values were generally lower in subjects
starting HAART in acute/early HIV-1 infection compared to
those starting during chronic infection (geometric mean values 47
vs. 93 copies/106; P= 0.30). The frequency of PBMC with HIV-1
DNA showed a modest but significant correlation with the time
between infection and the initiation of a suppressive HAART
regimen (r = 0.38, P= 0.037).
To determine whether HIV-1 DNA levels in PBMC could be
used as a surrogate measure of the size of the latent reservoir, we
examined the correlation between results of the viral outgrowth
assay on purified resting CD4+ T cells and the droplet digital PCR
assay for HIV-1 DNA in PBMC from the same blood sample. As
shown in Figure 2A and Table 4, there was essentially no
correlation between the two assays (r = 0.20, P= 0.29) for the
combined study population. Based on 95% confidence intervals
for r, a strong correlation (r.0.6) could be excluded (Table 4). For
patients treated during acute/early infection, a modest correlation
that did not reach statistical significance was observed (r = 0.46,
P= 0.18), but there was no correlation between the two assays for
patients initiating HAART during chronic infection (r =20.038,
P= 0.87).
HIV-1 DNA in purified resting CD4+ T cells
We next examined whether the correlation between the results
of the viral outgrowth and PCR assays might be improved if HIV-
1 DNA levels were measured in purified resting CD4+ T cells
instead of unfractionated PBMC. HIV-1 DNA was detected in
14/16 samples (Figure 1). The geometric mean level of HIV-1
DNA was 186 copies/106 resting CD4+ T cells. In two patients
(#2013, 2418), levels were below the limit of detection (2 copies/
106 resting CD4+ T cells). For these two subjects, cells with
replication-competent virus were readily measured in the virus
outgrowth assay (1.05 and 0.04 IUPM, respectively). As a measure
of infected cell frequency, the PCR assay gave substantially higher
values than did the viral outgrowth assay performed on the same
blood samples (186 vs. 0.62 infected cells/106 resting CD4+ T
cells, P,0.0001). This difference has been noted previously [5]
and may reflect the high fraction of proviruses that are defective
[41,42].
Cells harboring defective viral genomes could accumulate over
time during untreated disease. We did not, however, observed a
significant correlation between the frequency of resting CD4+ T
cells with HIV-1 DNA and the time between initial infection and
suppression of viral replication on HAART (r = 0.33, P = 0.20), the
time on a suppressive HAART regimen (r = 0.076, P= 0.78), or
the total time since infection (r = 0.30, P = 0.26).
If the proportion of defective proviruses was the same in
different patients, then the measurement of HIV-1 DNA in resting
CD4+ T cells from patients on HAART might provide a simpler
surrogate measure of the latent reservoir. However, as is shown in
Figure 3, the ratio of infected cells detected in the PCR vs. viral
outgrowth assays is highly variable from patient to patient (range
,2 to 3540) even when both assays are performed on the same
sample of purified resting CD4+ T cells. A subset of patients who
initiated therapy during chronic infection showed very high ratios
(.1000:1). For this reason, there is only a modest correlation
between the results of the two assays for the combined population
(Figure 2B and Table 4, r = 0.45, P= 0.08). In patients treated
during chronic infection, no correlation is observed (r = 0.10,
P= 0.76) The levels of HIV-1 DNA in unfractionated PBMC and
in purified resting CD4+ T cells showed a strong correlation
(r = 0.78, P= 0.0004). This reflects the fact that in patients on
HAART, the stable reservoir for HIV-1 is located primarily in
resting CD4+ T cells [6]. For most patients, infected cell
frequencies were higher in resting CD4+ T cells than in PBMC
(Figure 1). This is the expected result if most of the infected cells in
the blood are resting CD4+ T cells. However, if substantial
numbers of activated T cells and monocytes are infected, then the
resting CD4+ T cell value may not be higher. Chun and colleagues
have shown that even in patients on HAART, infected cells
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frequencies as measured by DNA PCR can be higher among
activated than resting CD4+ T cells [54].
Integrated HIV-1 DNA in PBMC and purified resting CD4+
T cells
Levels of integrated HIV-1 DNA were also measured in PBMC
and purified resting CD4+ T cells from study participants using a
previously described Alu PCR assay [39,40,55]. As shown in
Figure 1, integrated HIV-1 DNA was detected in 19/19 PBMC
samples, at a geometric mean frequency of 186 copies/106 PBMC.
The frequencies were significantly lower in patients starting
HAART in acute/early vs. chronic infection (84 vs 286 copies/106
PBMC, P= 0.04). As was observed with the droplet digital PCR
assay for HIV-1 DNA, levels of integrated HIV-1 DNA were
higher in purified resting CD4+ T cells than in unfractionated
PBMC (geometric mean values 604 vs 186 copies/106 cells,
Figure 1). Also consistent with the results of the droplet digital
PCR assay was the finding that the frequency of resting CD4+ T
cells with integrated HIV-1 DNA was much higher than the
frequency of latently infected resting CD4+ T cells detected in the
viral outgrowth assay performed on the same sample (by 1000
fold). In paired samples, the mean infected cell frequencies were
604 vs. 0.61/106 resting CD4+ T cells (P,0.0001).
Measurements of integrated HIV-1 DNA by Alu PCR and of
total HIV-1 DNA by droplet digital PCR correlated well with each
other both for samples of PBMC (Figure 2C, r = 0.63, P= 0.0042)
and resting CD4+ T cells (r = 0.85, P= 0.0079). These results are
consistent with the conclusion that in patients on long term
HAART, most of the HIV-1 DNA is integrated, with unintegrated
forms making only a minor contribution (see below) [38]. The fact
that infected cell frequencies detected by Alu PCR were higher
(186 vs 46 copies/106 PBMC, P= 0.0003) may reflect differences
in assay standardization. This assay provides definitive detection of
integrated HIV-1 DNA through the use of an initial PCR with a
primer in an Alu element and a primer in HIV-1. For each infected
cell, the distance to the nearest Alu element is different [56]. This
influences amplification efficiency, and some proviruses are
located too far from an Alu element to be detected. To circumvent
this problem, a correction is applied based on an integration
standard containing proviruses integrated at different distances
from the nearest Alu element [39,40,55]. The accuracy of the
method depends on how closely the distribution of provirus-Alu
element distances in the standard matches the distribution of
distances in a particular patient sample. It is possible that the
higher levels of integrated HIV-1 DNA detected in some patients
result from over-correction for proviruses missed by Alu-PCR.
Alternative explanations include underestimation of infected cell
frequency by droplet digital PCR or issues with the normalization
methods used in one or both assays.
Interestingly, there was a highly significant positive correlation
between the level of integrated HIV-1 DNA in PBMC and the
frequency of latently infected resting CD4+T cells determined in the
viral outgrowth assay on the same blood sample (Figure 2D and
Table 4, r = 0.70, P= 0.0008). When only patients starting HAART
during chronic infection were considered, the correlation remained
significant (r = 0.76, P= 0.0038). However, when the Alu PCR and
viral outgrowth assays were performed on the same sample of
purified resting CD4+ T cells, the correlation was weaker and not
statistically significant (r = 0.41, P= 0.13), possibly related to the
small number of samples and small number of genomes assayed.
HIV-1 DNA and RNA in rectal biopsy samples
Because the GALT is the site of very active viral replication in
untreated patients with acute HIV-1 infection [57–61], we
Figure 1. HIV-1 persistence assessed by six different assays performed on the indicated cell or tissue obtained from patients
starting HAART during acute/early infection (open symbols) or chronic infection (closed symbols). Geometric mean values are indicated
by a horizontal black line. Long red lines indicate the limit of detection (LOD) for the relevant assay with a standard input sample size. Short red lines
indicate patient-specific limits of detection in cases where the blood or tissue sample was smaller than normal. Negative assays are indicated by
samples plotted below the red LOD lines.
doi:10.1371/journal.ppat.1003174.g001
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Figure 2. Correlation between assays for HIV-1-infected cells in patients on HAART. (A) Correlation between infected cell frequencies
measured in the viral outgrowth assay on purified resting CD4+ T cells and the droplet digital PCR assay for HIV-1 DNA in unfractionated PBMC. (B)
Correlation between the viral outgrowth assay on purified resting CD4+ T cells and the droplet digital PCR assay for HIV-1 DNA in purified resting
CD4+ T cells. (C) Correlation between the droplet digital PCR assay for HIV-1 DNA and the Alu PCR assay for integrated HIV-1 DNA in PBMC. (D)
Correlation between the viral outgrowth assay on purified resting CD4+ T cells and the Alu PCR assay for integrated HIV-1 DNA in PBMC. (E)
Correlation between the viral outgrowth assay on purified resting CD4+ T cells from the blood and the PCR assay for HIV-1 DNA in rectal CD4+ T cells.
(F) Correlation between the viral outgrowth assay on purified resting CD4+ T cells from the blood and the single copy assay for residual viremia.
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measured levels of HIV-1 DNA and RNA in the rectal biopsy
samples from 19 study participants using qPCR. CD4+ T cells
were enumerated in each sample by flow cytometry, and results
were expressed as copies per CD4+ T cell. HIV-1 DNA was
readily detectable in all samples (Figure 1). The geometric mean
value for these 19 samples was 3015 copies/106 CD4+ T cells. In
paired comparisons, these values were significantly higher than the
levels of infection of resting CD4+ T cells from the peripheral
blood detected by digital droplet PCR (4282 vs. 263 copies/106
cells, paired t-test: P,0.0001) or by Alu PCR (2977 vs. 600 copies/
106 cells, paired t-test: P = 0.0008). The level of HIV-1 DNA in
rectal CD4+ T cells was not significantly correlated with the
frequency of latently infected resting CD4+ T cells in blood as
measured by the viral outgrowth assay (Figure 2E, r = 0.26,
P = 0.28). However, a strong correlation could not be formally
excluded based on 95% confidence intervals (r =20.22 to 0.64,
Table 4). There was a significant correlation between the level of
HIV-1 DNA in rectal biopsy samples and the frequency of infected
cells in the peripheral blood as measured by digital droplet PCR
(r = 0.58, P= 0.015) or by Alu PCR (r = 0.65. P= 0.016).
HIV-1 RNA was also detected by qRT-PCR in all samples. The
geometric mean level was 1985 copies/106 rectal CD4+ T cells.
These values cannot be used to establish infected cell frequencies
because of the likely presence of multiple HIV-1 RNA molecules
in some individual infected cells. Levels of HIV-1 RNA correlated
well with measures of HIV-1 DNA in the same samples
(r = 0.8811, P,0.0001). The geometric mean RNA/DNA ratio
was 0.68. RNA/DNA ratios in rectal biopsies were significantly
correlated with the frequency of resting CD4+ T cells in peripheral
blood that scored in the viral outgrowth assay (r = 0.57. P = 0.013).
2-LTR circles
2-LTR circles represent abortive integration events. They have
been used as a measure of recent infection in some studies, although
controversy remains about their stability [62–66]. 2-LTR circles were
measured in PBMC and purified resting CD4+ T cells from study
Patients starting HAART during acute/early or chronic infection are indicated by open or closed symbols, respectively. See Figure 1 for patient ID key.
The red lines indicate samples that fell below the limit of detection of the relevant assay. These samples were not used in the calculation of the
correlation coefficients.
doi:10.1371/journal.ppat.1003174.g002
Table 4. Correlation of PCR-based assays with viral outgrowth assay.
Patient populationsa: Total Acute Chronic
Assay rb 95% CIc Pd n rb 95% CIc Pd n rb 95% CIc Pd n
Droplet digital PCR for
HIV-1 DNA in PBMC
0.20 20.17 to 0.52 0.29 30 0.46 0.23 to 0.85 0.18 10 20.038 20.47 to 0.41 0.87 20
Droplet digital PCR for
HIV-1 DNA in resting
CD4+ T cells
0.45 20.06 to 0.77 0.08 16 0.10 20.53 to 0.66 0.76 11
Alu PCR for integrated
HIV-1 DNA in PBMC
0.70 0.36 to 0.88 0.0008 19 0.25 20.62 to 0.84 0.59 7 0.76 0.34 to 0.93 0.0038 12
Alu PCR for integrated
HIV-1 DNA in resting
CD4+ T cells
0.41 20.13 to 0.76 0.13 15 0.38 20.33 to 0.81 0.28 10
qPCR for HIV-1 DNA in
rectal biopsy CD4+ T cells
0.26 20.22 to 0.64 0.28 19 0.17 20.35 to 0.62 0.53 16
qPCR for HIV-1 RNA in
rectal CD4+ T cells
0.46 20.01 to 0.76 0.053 18 0.38 20.16 to 0.75 0.38 15
RNA/DNA ratio in rectal
CD4+ T cells
0.57 0.14 to 0.82 0.013 18 0.52 0.01 to 0.81 0.047 15
Droplet digital PCR for
2-LTR circles in PBMC
0.19e 20.18 to 0.52 0.31 30 0.12e 20.55 to 0.69 0.75 10 0.06e 20.39 to 0.49 0.81 20
Droplet digital PCR for
2-LTR circles in resting
CD4+ T cells
0.38e 20.15 to 0.74 0.15 16 0.037e 20.57 to 0.62 0.91 11
Single copy PCR assay
on plasma virus
0.070f 20.30 to 0.42 0.71 30 20.14f 20.71 to 0.54 0.71 10 0.14f 20.32 to 0.55 0.55 20
aCorrelations were analyzed for the entire study population (n = 30) and for subpopulations of study subjects starting HAART during acute/early (n = 10) or chronic
(n = 20) HIV-1 infection. Because of limitations in the size of blood or tissue samples, not all assays were performed for all subjects, and the n for each assay is shown in
the last column. Correlation coefficients were only computed for n.5.
bCorrelation coefficient for correlation with the viral outgrowth assay. Except where indicated, the Pearson correlation coefficient is shown.
c95% confidence intervals for the correlation coefficient. Strong correlations were considered to be formally excluded when the upper limit of the 95% confidence
interval was ,0.6.
dP values ,0.05 are indicated in bold type.
eBecause of the large number of samples in which 2-LTR circles were below the limit of detection (2 copies/106 cells), a Spearman’s rank correlation coefficient was
computed using a value of 1 copies/106 cells for the samples in which 2 LTR circles were not detected.
fBecause of the large number of plasma samples that had HIV-1 RNA levels below the limit of detection (0.2 copies/ml), a Spearman’s rank correlation coefficient was
computed using a value of 0.1 copies/ml for negative assays.
doi:10.1371/journal.ppat.1003174.t004
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subjects using droplet digital PCR (Figure 1). Circles were detected in
only 9 of 30 PBMC samples. Among these the geometric mean level
was 6.8 copies/106 PBMC. This was 27 fold lower than the total level
of HIV-1 DNA in the same samples measured by droplet digital PCR
(162 copies/106 PBMC, P,0.0001). As expected, levels of 2-LTR
circles in purified resting CD4+ T cells from peripheral blood were
higher than levels in unfractionated PBMC (geometric mean 13
copies/106 resting CD4+ T cells), but again this level was much lower
(by 34 fold) than the total level of HIV-1 DNA in the same samples
measured by droplet digital PCR (467 copies/106 resting CD4+ T
cells, P,0.0001). These results demonstrate that 2-LTR circles make
up only a small fraction of the total HIV-1 DNAmeasured by PCR in
patients receiving on HAART. By Spearman’s rank correlation
analysis, levels of 2-LTR circles in PBMC or resting CD4+T cells were
not significantly correlated with infected cell frequencies measured in
the viral outgrowth assay (rho=0.19, P=0.31 and rho=0.38,
P=0.15 respectively).
Single copy assay for residual viremia
Residual viremia was detectable in 20/30 study subjects, 13/20
in the chronic cohort and 7/10 in the acute cohort (Figure 1).
Among the patients with detectable residual viremia, the
geometric mean level was 0.78 copies/ml, consistent with previous
studies [46,47,67]. There was no significant difference between the
acute and chronic cohorts in the proportion of patients with
detectable residual viremia (7/10 vs. 13/20) or in the level of
detectable residual viremia (0.84 vs. 0.75 copies/ml, P = 0.75).
Scatter plots show no obvious correlation between residual viremia
and the viral outgrowth assay (Figure 2F). We considered the
possibility that such a correlation could have been obscured by the
failure to detect residual viremia in one third of the subjects.
Negative results in the single copy assay could be due to primer
mismatch or levels of residual viremia below the detection limit
[47]. If patients for whom the single copy assay was negative are
excluded, the correlation between residual viremia and the
frequency of latently infected cells in the viral outgrowth assay is
weak (r = 0.24, P= 0.33). If all patients are included in the analysis
and a single copy assay value of 0.1 copies/ml is assumed for those
patients with negative results in this assay, the rank correlation is
also very weak (rho= 0.070, P= 0.71). Thus regardless of whether
the negative values in the single copy assay represent primer
mismatch or values below the limit of detection, it is difficult to
Figure 3. Ratio of infected cell frequencies determined by droplet digital PCR for HIV-1 DNA or by viral outgrowth assay. Analysis
was done on the same sample of purified resting CD4+ T cells. * indicates maximum values in cases in which the HIV-1 DNA level was below the limit
of detection (2 copies/ml).
doi:10.1371/journal.ppat.1003174.g003
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construct a scenario where there is strong correlation between
residual viremia and the viral outgrowth assay. A strong
correlation could be formally excluded for the total population
and for subpopulations starting HAART during acute/early or
chronic infection. Residual viremia was not correlated with the
level of infection in PBMC by droplet digital PCR (rho=20.25,
P = 0.18), the level of infection of CD4+ T cells in the rectal
biopsies (rho= 0.12, P= 0.61), or the level of 2LTR circles
(rho=20.109, P= 0.57). Because the limit of detection of this
assay with a sample volume of 8 ml is 0.2 copies/ml, a one log
reduction in the size of viral reservoirs contributing to residual
viremia would render values unmeasurable.
Discussion
With the discovery of new agents that reactivate latent HIV-1,
clinical trials of HIV-1 eradication strategies have begun [32]. No
available clinical assay measures the size of the latent reservoir.
Patients being enrolled in eradication studies have been on
HAART for years and already have undetectable levels of viremia
by standard clinical assays (detection limit 50 copies/ml).
Therefore, there is an urgent need for laboratory assays to
determine the efficacy of eradication strategies. Here we compare
eleven different approaches for quantitating persistent HIV-1 in
patients on HAART. The analysis involved seven analytical
approaches and four different kinds of tissue samples. Assays were
carried out using well characterized patients on long term stable
HAART. Results were compared to the viral outgrowth assay that
was originally used to define the latent reservoir [5,6,9,10,33].
We first evaluated PCR assays for HIV-1 DNA in unfraction-
ated PBMC or resting CD4+ T cells. PCR quantitation of HIV-1
DNA in unfractionated PBMC perhaps offers the best chance for a
scalable, high throughput assay for the latent reservoir. Using a
novel droplet digital PCR assay, we detected HIV-1 DNA in
PBMC from 28/30 subjects, with a mean infected cell frequency
more than 100 fold higher than the mean frequency of resting
CD4+ T cells that release replication-competent virus in the viral
outgrowth assay. An even greater difference was observed when
the viral outgrowth and droplet digital PCR assays were run on the
same sample of purified resting CD4+ T cells. In part, this
difference is likely to reflect the detection by PCR methods of cells
harboring defective viral genomes such as cells with viral genomes
that have been lethally hypermutated by APOBEC3G [42]. The
difference between viral outgrowth and PCR-based assays was also
observed in patients who start HAART in acute/early HIV-1
infection, suggesting that it is not simply the result of accumulation
of cells with defective viruses over time. If a constant proportion of
the infected resting CD4+ T cells contained defective genomes,
then PCR measurements might provide a reliable surrogate
measure of reservoir size in cross-sectional analysis. However, for
the whole study population and the subset initiating HAART
during chronic infection, a strong correlation (r.0.6) between
results of the PCR assay for HIV-1 DNA and the viral outgrowth
assay can be formally excluded. A larger sample size is needed to
determine whether some correlation exists for patients initiating
HAART early. It is possible that as the infection progresses, cells
with defective viral sequences accumulate at different rates in
different patients so that there is eventually very little correlation
between the viral outgrowth assay and PCR-based assays. The
ratio of infected cell frequencies determined by the two different
assays varies by over 3 logs, with a subset of the patients who
initiated therapy during chronic infection showing very high ratios.
Taken together, these results are consistent with the hypothesis
that differential accumulation of resting CD4+ T cells with
defective viral sequences obscures the relationship between the
frequency of cells detected in the virologic and molecular assays.
Most patients start therapy during chronic infection, and it is
problematic that readily scalable PCR assays for total HIV-1 DNA
on PBMC do not provide a precise reflection of the size of the
latent reservoir, at least for cross-sectional analysis. It remains
possible that PCR assays will be useful in following individual
patients participating in eradication trials, but it is not yet clear
that latency-reversing strategies will cause proportionate reduc-
tions in the latent reservoir and in the total pool of cells with HIV-
1 DNA. For example, some cells with defective viral genomes may
not express viral genes in response to latency-reversing agents.
Hypermutated genomes typically have stop codons in every open
reading frame [42], and thus cells carrying hypermutated genome
may not be eliminated by latency reversing strategies that depend
on viral cytopathic effects or CTL-mediated clearance. These cells
might still be detected by PCR-based assays even when cells with
replication-competent viral genomes were being eliminated.
Initial studies established that the latent reservoir in resting
CD4+ T cells consists of cells with stably integrated viral genomes,
[4,5]. We therefore evaluated a well established Alu PCR assay
specific for integrated viral genomes. Infected cell frequencies
determined by this method were similar to and well correlated
with frequencies determined by the droplet digital PCR assay,
which does not distinguish integrated and unintegrated viral
genomes (r = 0.85, P= 0.0079 for resting CD4+ T cells). These
results are consistent with the notion that most of the HIV-1 DNA
in resting CD4+ T cells of patients on HAART is integrated.
Linear unintegrated forms, which are prevalent in untreated
patients [35], are labile [37,68] and are not seen in the absence of
ongoing viral replication. Circular unintegrated forms (2-LTR
circles), when detected, were present only at extremely low levels.
Although levels of integrated HIV-1 DNA correlate well with
measurements of HIV-1 DNA by the droplet digital PCR assay,
both assays can detect defective as well as replication-competent
proviruses. Among the approaches evaluated, analysis of integrat-
ed HIV-1 DNA in PBMC showed the best correlation with results
of the viral outgrowth assay on purified resting CD4+ T cells
(Table 4, r = 0.70, P = 0.0008). The correlation was weaker when
integrated HIV-1 DNA was measured in purified resting CD4+ T
cells.
Because the GALT provides a major site for HIV-1 replication
[57–61], we also measured the HIV-1 DNA and RNA levels in
rectal biopsy samples. When normalized for the number of CD4+
T cells present, the DNA PCR assay gave infected CD4+ T cell
frequencies that were significantly higher than infected cell
frequencies in the blood, consistent with previous studies
[43,44]. HIV-DNA levels in rectal biopsy samples showed a
modest correlation with HIV-1 DNA levels in cells from the
peripheral blood, but not with results of the viral outgrowth assay.
Overall, these results highlight the potential importance of the
GALT as an HIV-1 reservoir. However several critical questions
remain. It is important to understand the fraction of CD4+ T cells
in the GALT that can produce replication-competent virus and
whether or not the virus is generally latent in these sites. The HIV-
1 RNA/DNA ratios measured in these samples were generally,1,
but these values are difficult to interpret because of uncertainty
regarding the distribution of RNA molecules among infected cells.
Interestingly, RNA/DNA ratios in rectal biopsy samples showed a
statistically significant correlation with the viral outgrowth assay
(r = 0.57, P= 0.013). This may reflect the fact that the RNA:DNA
ratio provides some indication of the number of infected cells that
have the capacity to produce viral RNA.
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As a measure of viral persistence, the single copy assay for
residual viremia is of particular interest because it detects ongoing
virus production in patients on suppressive HAART regimens.
Residual viremia was only detectable in two thirds of study
subjects and did not correlate with infected cell frequencies as
measured by the viral outgrowth assay. A precise correlation might
be expected if the activation of latently infected resting CD4+ T
cells was the major source of residual viremia. However, recent
studies [69–71] have show that in many patients the residual
viremia is dominated by viral clones that are profoundly
underrepresented in resting CD4+ T cells from the peripheral
blood, suggesting an additional source of residual viremia.
Another important factor in evaluating assays for persistent
HIV-1 is the dynamic range. Specifically, it is important to
understand how much of a reduction in the reservoir would be
measurable with each assay assuming reasonable sample volumes.
Among the assays evaluated, the single copy assay for residual
viremia has the lowest operating range. The viral outgrowth assay
is already run on large blood volumes (180 ml), and its dynamic
range cannot be extended much further. PCR-based assays
perhaps offer the largest dynamic range, but suffer from the
caveats discussed above.
Other studies have compared assays for persistent HIV-1, and
the results differ to some extent from the findings presented here.
In an early study, Anton et al. compared several measures of
persistent HIV-1 infection in patients on HAART [72]. Although
these investigators noted some modest correlations between the
results of different culture and PCR-based assays, their findings
cannot be readily compared to those of the present study because
the culture assays were not run on purified resting CD4+ T cells
and the PCR-based assays were not normalized for input CD4 cell
number. Chun et al. reported a weak but statistically significant
correlation (r = 0.29, P = 0.001) between linear values for residual
viremia measured with an assay that has a detection limit of 20
copies/ml and the level of HIV-1 DNA in resting CD4+ T cells
[73]. Murray et al. [74] observed an accumulation of cells with
HIV-1 DNA during the first two years of untreated HIV-1
infection, consistent with the differences in infected cells frequen-
cies between the acute and chronic cohorts in our study. Cells with
defective proviruses may fail to express viral proteins and may
therefore be protected from viral cytopathic effects and host CTL.
The cells will thus have a chance to accumulate. This may happen
at different rates in different patients, greatly complicating
measurement of the reservoir by PCR-based approaches. Of note,
no other study has shown a precise correlation between the results
of the viral outgrowth assay and any simpler assay.
Overall, the results of this study suggest that no PCR-based
assay provides a precise and internally consistent indication of the
amount of replication-competent HIV-1 in resting CD4+ T cells.
These findings raise the important issue of how to quantify
decreases in the latent reservoir in future HIV-1 eradication trials.
The fundamental problem is that infected cell frequencies
determined by PCR-based assays are at least 2 logs higher than
infected cell frequencies determined by the viral outgrowth assay.
Much of this difference may be due to cells carrying defective
proviruses, for example those that have been lethally hypermu-
tated by APOBEC3G. These defective proviruses may not be
eliminated by strategies designed to target latently infected cells. In
this situation, successful clearance of latently infected cells might
be masked by a larger and unchanging pool of cells with defective
proviruses. While PCR-based assays may overestimate the size of
the reservoir, the viral outgrowth assay provides only a minimal
estimate of the frequency of cells harboring replication-competent
virus. The assay conditions were carefully chosen to induce blast
transformation in 100% of the input resting CD4+ T cells [6]. In
this situation, the failure of an infected cell to produce replication-
competent virus can be due to defects in the provirus such as
APOBEC3G-induced hypermutation [42] or large internal
deletions [41]. However, epigenetic silencing [75], transcriptional
interference [76,77], and other factors could also in principle
prevent some proviruses without intrinsic defects from scoring in
the viral out growth assay. Importantly, no other culture assay,
including those that use alternative T cell activating stimuli [7,8],
has detected a higher frequency of cells with replication-competent
virus. Nevertheless, the development of assays that precisely
quantitate the number of the latently infected cells that have the
potential to release replication-competent virus in vivo is an
important goal in eradication research.
Materials and Methods
Patient cohorts
This study enrolled 30 patients from two well established
cohorts at the University of California San Francisco (UCSF). All
study subjects provided informed consent. Twenty patients were
from the SCOPE cohort, an ongoing longitudinal study of ,1500
HIV-1-infected and uninfected adults. Infected individuals in this
cohort started HAART during chronic infection (.180 days from
estimated date of infection). Subjects were seen and interviewed at
four-month intervals to ascertain: (1) current medications, (2)
medication adherence, (3) recent intercurrent illnesses, and (4)
recent diagnoses or hospitalizations. Plasma HIV-1 RNA levels
and routine T cell immunophenotyping were performed at each
visit.
Ten patients were recruited from the OPTIONS cohort, an
ongoing longitudinal study of adults enrolled within 8 months of
HIV-1 infection. The evaluation of patients with possible acute
infection included detailed HIV-1 testing and exposure history and
the following laboratory studies: (1) a high-sensitivity assay for
plasma HIV-1 RNA, (2) a standard HIV-1 antibody EIA with
western blot confirmation if positive, and (3) a less-sensitive
(detuned) antibody EIA (LS-EIA). Screened subjects met one or
more of the following criteria to be defined as having primary or
recent HIV-1 infection: (1) repeated plasma HIV-1 RNA .5,000
copies/ml combined with a negative or indeterminate HIV-1
antibody test; (2) seroconversion within 6 months of a documented
negative HIV-1 antibody test or (3) a history compatible with
primary HIV-1 infection (including no prior positive HIV-1
antibody tests) and laboratory testing consistent with recent
infection on the ‘‘detuned’’ antibody EIA. Eligible subjects were
followed approximately every 3 months.
Eligibility criteria for all patients enrolled in the present study
included: (1) confirmed HIV-1 infection, (2) documented prior
initiation of one of the Department of Health and Human Services
recommended/alternative HAART regimens [78], (3) at least 36
months of continuous HAART at study entry with no regimen
changes in the preceding 24 weeks, (4) maintenance of plasma
HIV-1 RNA levels below the limit of detection of conventional
assays for at least 36 months (intermittent isolated episodes of
detectable low-level viremia were allowed), (5) most plasma HIV-1
RNA levels below the level of detection (,40 copies RNA/ml),
and (6) documented CD4+ T-cell count above 350 cells/ml for
preceding 24 weeks. We excluded subjects who (1) had recent
hospitalization, (2) recent infection requiring systemic antibiotics,
(3) recent vaccination or (4) exposure to any immunomodulatory
drug (including maraviroc) in the preceding 16 weeks.
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Patient samples
All subjects who met entry criteria for screening and agreed to
participate in the study had an initial structured interview,
phlebotomy, and HIV-1 testing using the established SCOPE
and OPTIONS infrastructure. Once eligibility for the large
volume blood draw (220 ml) and gut biopsy procedures were
determined, blood was collected in tubes containing acid-citrate-
dextrose (ACD), and 180 ml of the sample were shipped overnight
at ambient temperature to the Johns Hopkins School of Medicine
where peripheral blood mononuclear cells (PBMC) and resting
CD4+ T lymphocytes were isolated for quantitative studies of
proviral DNA and replication competent virus. Extensive previous
studies have shown that cells can be recovered with high viability
for virus culture assays after overnight shipment [79]. The
remaining peripheral blood (40 ml) was sent to the UCSF AIDS
Specimen Bank for studies of the host response and additional
virologic studies.
At John Hopkins, PBMC were isolated using density gradient
centrifugation. Supernatant plasma was frozen at 280uC and sent
on dry ice to Dr. Sarah Palmer of the Karolinska Institute in
Stockholm, Sweden for the single copy assay for plasma HIV-1
RNA [46]. Aliquots of PBMC were frozen as cell pellets for
analysis of total and integrated HIV-1 DNA. Resting CD4+ T cells
were purified from PBMC by negative depletion using biotinylated
antibodies and anti-biotin magnetic beads. Briefly, CD4+ T
lymphocytes were first isolated from PBMC by removing
unwanted cell populations (CD4+ T cell Isolation Kit II; Miltenyi).
Non-CD4+ T cells were labeled first with a cocktail of biotin-
conjugated monoclonal antibodies followed by incubation with
anti-biotin-conjugated magnetic microbeads. Unwanted cells were
then removed using a LS MACS Column with the MACS
Separator magnet (Miltenyi). Activated CD4+ T lymphocytes were
then removed from the total CD4+ T cell population by labeling
unwanted cells with biotin-conjugated antibodies to CD25, CD69,
and HLA-DR and anti-biotin microbeads (Miltenyi). Labeled cells
were magnetically removed using MACS MS columns with the
MACS separator. The resting CD4+ T cell population was
typically 98–99% pure as assessed by FACS analysis. Latent HIV-
1 in resting CD4+ T cells was quantitated using the viral outgrowth
assay (see below). Aliquots of purified resting CD4+ T cells were
frozen as cell pellets and sent along with aliquots of unfractionated
PBMC to UCSD and the University of Pennsylvania for assays of
total and integrated HIV-1 DNA. Details of individual assays are
given below.
A subset of study subjects underwent a rectosigmoid biopsy at
San Francisco General Hospital. Up to 30 3-mm biopsies were
obtained 10–30 cm above the anus with a disposable biopsy
forceps (3.3-mm outside diameter). Biopsy specimens were
suspended in RPMI 1640 containing 10% fetal calf serum,
piperacillin–tazobactam (500 mg/ml), and amphotericin B
(1.25 mg/ml), and transported within 2–3 h to the UCSF Core
Immunology Laboratory where the tissue was digested with
collagenase and needle shearing (see below). Cells were counted
and frozen as cell pellets until analyzed for HIV-1 DNA and RNA.
Ethics statement
Blood and rectal biopsies from patients were obtained through
protocols approved by the UCSF Committee on Human
Research. For the virus culture assay, blood was obtained from
healthy donors through a protocol approved by the Johns Hopkins
University School of Medicine Internal Review Board #4. All
study subjects provided written informed consent prior to
participation in the study.
Assays
Viral outgrowth assay. The principal assay used to define
the latent reservoir in resting CD4+ T cells is a limiting dilution
virus culture assay [5,6,9,10,33]. This assay was performed as
previously described [33] except that purification of resting CD4+
T cells was carried out using the two step magnetic bead depletion
protocol described above instead of bead depletion followed by
flow sorting. Five-fold serial dilutions of highly purified resting
CD4+ T cells were stimulated with the mitogen PHA and a ten
fold excess of irradiated allogeneic PBMC. This stimulation
induces global T cell activation which reverses latency at least in a
fraction of cells carrying integrated HIV-1 genomes. The release of
replication-competent virus was detected by adding CD4+
lymphoblasts from HIV-1-negative donors. The virus replicates
in these cells and after 2–3 weeks of culture, supernatants contain
sufficient levels of virus that an ELISA assay for HIV-1 p24
antigen can be used to detect positive wells. CD8+ T cells, which
can suppress viral replication, were depleted from the lympho-
blasts that were added to the culture assay. The frequency of HIV-
1 infected cells was determined by a maximum likelihood method
[33].
Digital droplet PCR for total HIV-1 DNA. Cellular DNA
was extracted using a Qiagen DNA Blood Midi Kit, following the
manufacturer’s protocol. DNA was ethanol precipitated following
elution to increase concentration. The DNA concentration was
estimated from the A260/A280 absorptivity ratio using a
NanoDrop 2000 spectrophotometer (Thermo Scientific). When
the DNA concentration was below the desired concentration for
emulsification, the concentration was increased by ethanol
precipitation and re-suspension. Where specified, templates were
thoroughly mixed with background human genomic DNA
obtained by identical extraction methods from HIV-1 seronegative
donors (‘‘PBMC DNA’’) or with sonicated salmon sperm DNA
(Agilent Technologies). Extracted DNA was heated to 95uC for
10 minutes, then quenched on ice prior to digestion with the
restriction enzyme BSAJ-I (New England Biolabs) at 60uC for
1 hour. Plasmids encoding the entire HIV-1 genome (pNL4-3,
AIDS Reference Research Reagent Repository) or a 2-LTR
junction (a kind gift from Dr. Kristine Yoder, Ohio State
University) were used as standards. Primers to conserved regions
of HIV-1 pol (HXB2 positions 2536-2662) and to the HIV-1 LTR
(HXB2 positions 9585-51) were used. An RPP30 (RNAse P)
primer/probe set was used for host genomic DNA quantification.
Samples were diluted 10-fold and RPP30 was assayed without
multiplexing. The PCR reaction mixture was loaded into the Bio-
Rad QX-100 emulsification device, and droplets were formed
following the manufacturer’s instructions. The contents were
transferred to a 96-well reaction plate and sealed with a pre-heated
Eppendorf 96-well heat sealer for 2 seconds, as recommended by
Bio-Rad. Total DNA was amplified separately in an Applied
Biosystems GeneAmp 9700 thermal cycler. Each reaction
consisted of a 20 mL solution containing 10 mL ddPCR Probe
Supermix, 900 nM primers, 250 nM probe, and template DNA
with the following cycling conditions: 10 minutes at 95uC, 40
cycles each consisting of a 30 second denaturation at 94uC
followed by a 58uC extension for 60 seconds, and a final
10 minutes at 98uC. After cycling, droplets were analyzed
immediately or stored at 4uC overnight and until analysis.
Raw fluorescence data for each well were exported from the
manufacturer’s software (Bio-Rad QuantaSoft v. 1.2) for analysis.
Analysis of individual event data was performed using custom
software written in Mathematica 8.0 (Wolfram Research).
Droplets were classified as positive, negative or ambiguous
following a custom algorithm that filters out potentially spurious
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events (Strain et al., manuscript submitted). Events that remained
ambiguous after all data processing were excluded. The number of
template copies per unit volume m was estimated from the number
of positive events n detected in the corresponding channel and the
number of total accepted droplets N by maximum likelihood. The
distribution of templates within a drop was assumed to follow a
Poisson distribution, and the number of positive droplets was
assumed to follow a binomial distribution. Confidence intervals
were estimated under the same assumptions. The droplet size was
assumed to be 0.91 nl, consistent with the instrument manufac-
turer’s software. Template copies per sample were computed by
averaging over all available replicate wells. Total cellular DNA
input was measured by halving the estimated number of RPP30
copies, and copy numbers per diploid cell equivalent were
computed as the ratio of template (pol or 2-LTR) copies per
diploid cell. Statistical analyses were performed using Graph-Pad
Prism 5.0 software (GraphPad Software, Inc.) and Mathematica
8.0.
Measurements of integrated HIV-1 in resting CD4+T cells
and PBMC. Integrated HIV-1 DNA was measured in PBMC or
purified resting CD4+ T cells using a previously described Alu PCR
[39,40,55,80]. This assay detects only integrated proviruses
because it relies on an initial amplification in which one primer
hybridizes with a conserved sequence in Alu elements which are
present in ,2,000,000 copies in the human genome. The Alu
primer is paired with an HIV-1 gag primer in the first round of
amplification. This Alu-gag amplification is then followed by a
second amplification that targets a sequence in the HIV-1 LTR
(R-U5). The level of HIV-1 integration is quantitated by
comparing the detection signal to an integration standard curve
that correlates cycle thresholds with integration standard copy
number. The integration standard was especially produced to
contain genomes with integration sites at a variety of distances
from Alu sites, mimicking the pattern of integration seen in natural
infection [80]. DNA was isolated from frozen PBMC and resting
CD4+T cell pellets using the Gentra Puregene Cell Kit (Qiagen)
following the manufacturer’s instructions. DNA was then diluted
to 2 ug/mL and assayed in 42 replicates for integrated HIV-1
proviruses as previously described [54]. The first step reaction was
performed for 40 cycles at the following conditions: 95uC for 15 s,
50uC for 15 s and 72uC for 3 min 30 s. Simultaneously and on the
same plate, 42 reactions with only the gag primer were also
performed following the same conditions. The product from the
first step reaction was then diluted 1:2 into the 2nd step master mix.
The second step was performed on an ABI 7500 FAST instrument
following the FAST protocol (95uC for 0:03 and 60uC for 0:30) for
50 cycles. The cycle threshold values are then used to calculate an
integration value using a standard curve as described [55]. In
samples with low levels of integrated HIV-1 DNA (with integration
detectable in ,30% of wells), the percent positive method for
calculation was utilized. In these cases, a cutoff value was
generated by subtracting two standard deviations from the average
of the cycle threshold values for PCR reactions with only the gag
primer present in the first step. Any wells with a cycle threshold
less than this cutoff value were considered ‘‘positive’’ signals. The
percent of positive signals is calculated by dividing the wells
counted by the total number of wells assayed (containing both the
Alu and gag primers). A standard curve [55] showing a linear
relationship between the copies of integrated HIV-1 and the
percent of positive wells was used to calculate copy number in
several of these samples. Occasionally, samples had too little DNA
to do 42 replicates.
Assays for HIV-1 DNA and RNA in GALT. Rectal biopsy
samples were separated into single cells using a modification of a
published method [44,81,82]. Briefly, biopsies were subjected to
three rounds of collagenase digestion, mechanical disruption (by
passing through a blunt 16 gauge needle), clarification (by passing
through a 70 mm cell strainer), and washing. The three aliquots of
strained and washed cells were then combined, counted, and
aliquoted for flow cytometry and nucleic acid extraction. For
extraction, cells were lysed using 1 ml of Qiazol reagent (Qiagen),
followed by 15 min centrifugation at 12,000 g at 4uC. RNA was
extracted from the aqueous layer using the miRNeasy Mini kit
(Qiagen) with on-column DNAase treatment (Qiagen RNase-Free
DNase Set) and eluted in 30 ml of RNase-free water. DNA was
extracted from the organic layer using 0.5 ml of back extraction
buffer (4 M guanidine thiocyanate, 50 mM Na citrate, and 1 M
Trizma base), followed by precipitation with 500 ml of isopropa-
nol, 2 washes with 75% ethanol, and resuspension in 100 ml of EB
buffer (Qiagen). RNA and DNA concentrations were measured
using a ND-1000 spectrophotometer (NanoDrop).
Three replicate samples of 500 ng of DNA from each donor
were assayed for total HIV-1 DNA using a modification of a
published real time Taqman PCR assay that uses primers and a
probe from the LTR region and can detect a single copy of HIV-1
in brain tissue [4]. Primers were F522-43 Kumar (59 GCC TCA
ATA AAG CTT GCC TTG A 39; HXB2 522–543) and R626-43
Kumar long (59 GGG CGC CAC TGC TAG AGA 39; 626–643).
The probe, 59 CCA GAG TCA CAC AAC AGA CGG GCA CA
39, was dual-labeled with 6-FAM(59) and Black Hole Quencher
BHQ-1(39). Reaction volume was 50 ml with 25 ml of 26 Gene
Expression Master Mix (Applied Biosystems), 10 pmol of each
primer, 10 pmol of probe, and 5 ml of DNA (100 ng/ml). Cycling
conditions were: 50uC for 2 min, 95uC for 10 min, then cycles of
95uC for 15 s and 59uC for 1 min. External standards (105 to 1)
were prepared from DNA extracted from known numbers of 8E5
cells (NIH AIDS Reagent Program), each of which contains one
integrated HIV-1 genome per cell.
HIV-1 DNA copy numbers were measured in triplicate and
normalized to cellular input, as determined by DNA concentration
(assuming 1 mg total DNA corresponds to 160,000 cells). To
account for variation in the number of CD4+ T cells in different
samples, results were further normalized by the percent of all cells
that were CD45+CD3+CD4+ (by flow cytometry) and expressed as
copies/106 CD4+ T cells [44]. This normalization is based on the
assumption that most of the HIV-1 DNA in rectal cells is in CD4+
T cells. This assumption is based on a recent analysis of sorted
rectal cell populations that found ,90% of the HIV-1 DNA to be
in CD4+ T cells (S. Yukl, unpublished results).
Three replicates of up to 500 ng of RNA from each sample
were assayed for total processive HIV-1 RNA transcripts using
primers and probe from the LTR region (as above). Reaction
volume was 50 ml with 25 ml of 26 One Step RNA-to-Ct mix
(Applied Biosystems), 10 pmol of each primer, 10 pmol of probe,
1.25 ml of 406 RT (Applied Biosystems), and 5 ml of RNA
(100 ng/ml). Cycling conditions were: 48uC for 20 min, 95uC for
5 min, then 60 cycles of 9u5C for 15 s and 59uC for 1 min.
External standards (2.5 to 2.56105) of genomic HIV-1 RNA were
prepared by extracting the RNA from lab stocks of NL4-3 virions
(using the QIAmp Viral RNA Mini Kit) and then quantifying the
RNA via replicate measurements using the Abbot Real Time
assay.
HIV-1 RNA copy numbers were measured in triplicate and
normalized to cellular input into the PCR, as determined by RNA
concentration (assuming that 1 ng RNA correspond to 1000 cells
[83]), which has been shown to correlate with levels of
glyceraldehyde phosphate dehydrogenase (GAPDH) RNA [44].
As an alternative method of normalizing to cell numbers, all RNA
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samples were assayed for GAPDH in triplicate by qRT-PCR with
the conditions above, except with 2.5 ml of 206GAPDH primer/
probe mix [Applied Biosystems] and 3 ml of RNA. To account for
variation in the number of CD4+ T cells in different samples, HIV-
1 RNA copy numbers were further normalized by the percent of
all cells that were CD45+CD3+CD4+ [44].
Single copy assay for residual viremia. The concentration
of HIV-1 RNA in plasma was determined as previously described
[46,47,67]. To control for recovery of HIV-1, each plasma sample
is spiked with 30,000 copies of an internal virion standard derived
from an unrelated retrovirus, the replication competent avian
sarcoma-leukosis retrovirus vector RCAS BP(A). For samples
expected to have ,50 copies of HIV-1 RNA/ml, 8 ml of plasma
were used. Total RNA was extracted from the pellet using
proteinase K and guanidinium isothiocyanate and used as a
template for reverse transcription and real-time PCR of a small
(79 bp), highly conserved, coding sequence in HIV-1 gag. Using
this primer and probe set, HIV-1 RNA can be amplified from
about 80% of those infected with HIV-1 subtype B. PCR products
are detected using fluorescent probes. For each plasma sample, 3
independent reactions were run with HIV-1 gag-specific primers
and two with RCAS BP(A) gag-specific primers. The quantity of
HIV-1 RNA in the original plasma sample was calculated from a
standard curve generated for each assay using serial dilutions of in
vitro transcripts of the same region of gag. Control experiments
have shown that the recovery of HIV-1 RNA and RCAS BP(A)
RNA was comparable and independent of the original plasma
volume used in the range of 1–8 ml.
Statistical methods
Acute/early and chronic cohorts were compared using 2-tailed t
tests for independent samples. Log transformed virologic data met
the D’Agostino-Pearson test for Normal distribution, and corre-
lations were performed on log transformed data. For DNA PCR
measurements of cell associated HIV-1 genomes, we assumed that
infected cells carried a single provirus [84] and expressed the
results as the frequency of infected cells. For culture assay and
HIV-1 DNA data, one or two samples were below the limit of
detection of the relevant assays. For these, an imputed value
representing the lower of the limit of detection or a value
corresponding to 1 percentile of a log normal distribution fitted to
the measured values was used in the calculation of the Pearson
correlation coefficient. In the case of the single copy assay for
HIV-1 RNA in plasma, for which one-third of the measurements
were below the limit of detection (0.2 copies/ml), a low imputed
value of 0.1 was used to calculate the Spearman rank correlation
coefficient. Similar results were obtained when an imputed value
of 0.01 was used. Data analysis was done using Microsoft Excel
and MedCalc software.
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